ERT and Science 37 Partner to Deliver High-Quality Data During Virtual Trials

ERT, the global leader in clinical endpoint data collection and Science 37, the leader in decentralized clinical trials, have forged a partnership enabling ERT’s Cardiac Safety, Respiratory, and Imaging solutions to be incorporated into the Science 37 virtual, or decentralized clinical trial offering. The combined solution significantly improves data quality while dramatically reducing patient burden.

In a traditional clinical research model, many patients travel long distances and risk increased exposure to COVID-19 and other infectious diseases to participate at a clinic. In a virtual trial, patients participate from the comfort of their own home and effectively bypass these obstacles. Both approaches require the same level of data integrity and proven endpoint technologies. 
 
The ERT and Science 37 partnership enables sponsors to capture the same high-quality data in a virtual model as it would in a traditional model, while reducing patient burden, minimizing patient risk and enabling study continuity.
 
“Given the challenges caused by COVID-19, trial sponsors need effective virtual trial solutions that enable patients to participate safely, without jeopardizing data quality,” said Jim Corrigan, CEO at ERT. “We’re pleased to partner with Science 37 and to expand the use of our Respiratory, Cardiac Safety and Imaging solutions to support virtual trials throughout the pandemic and beyond.”
 
During home and telemedicine visits, Science 37 will use ERT’s proven remote respiratory and cardiac safety data collection solutions. Additionally, Science 37 will leverage ERT’s Imaging services through a local-care network—helping to limit patient travel with medical imaging services closer to home. 

“We are delighted to partner with ERT and to work together in bringing these best-in-class offerings to patients and sponsors,” says David Coman, CEO of Science 37. “As we make virtual trials the new reality, this partnership enables us to reduce patient burden and provide the high-quality data trial sponsors require as they evaluate the safety and efficacy of new medical treatments.”